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Sodium channel gene family: epilepsy mutations, gene
interactions and modifier effects
Miriam H. Meisler, Janelle E. O’Brien and Lisa M. Sharkey
Department of Human Genetics, University of Michigan, Ann Arbor MI 48109-5618, USA
The human sodium channel family includes seven neuronal channels that are essential for
the initiation and propagation of action potentials in the CNS and PNS. In view of their
critical role in neuronal firing and their strong sequence conservation during evolution, it
is not surprising that mutations in the sodium channel genes are responsible for a growing
spectrum of channelopathies. Nearly 700 mutations of the SCN1A gene have been identified
in patients with Dravet’s syndrome (severe myoclonic epilepsy of infancy), making this the
most commonly mutated gene in human epilepsy. A small number of mutations have been
found in SCN2A, SCN3A and SCN9A, and studies in the mouse suggest that SCN8A may also
contribute to seizure disorders. Interactions between genetic variants of SCN2A and KCNQ2
in the mouse and variants of SCN1A and SCN9A in patients provide models of potential
genetic modifier effects in the more common human polygenic epilepsies. New methods for
generating induced pluripotent stem cells and neurons from patients will facilitate functional
analysis of amino acid substitutions in channel proteins. Whole genome sequencing and exome
sequencing in patients with epilepsy will soon make it possible to detect multiple variants and
their interactions in the genomes of patients with seizure disorders.
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Introduction
The human genome contains ten paralogous genes
encoding the large transmembrane protein that
constitutes the pore-forming α-subunit of the
voltage-gated sodium channel. Two clusters of tandemly
duplcated genes are located on chromosomes 2q24 and
3p22, and two single genes are located on chromosomes
12q13 and 17q23 (Fig. 1). All of these genes except SCN7A
encode proteins that exhibit sodium channel activity in
exogenous expression systems. During the evolution of
this gene family its members have diverged with respect
to tissue-specific expression; the major expression site
for each gene is shown in Fig. 2. The basic architecture
of the four-domain protein with its 24 transmembrane
segments (Fig. 2) is conserved in all family members,
and the amino acid sequence identity varies from 50%
to 85% between channels. In this review we address the
roles of these channels and their mouse orthologues in
epilepsy.
SCN1A
Mutations in SCN1A encoding the sodium channel
Nav1.1 are the most common genetic cause of inherited
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and sporadic epilepsy. SCN1A mutations were first
identified in families with the mild inherited disorder
generalized epilepsy with febrile seizures plus (GEFS+)
(Escayg et al. 2000) and shortly thereafter in sporadic
patients with the early onset, severe progressive disorder
severe myoclonic epilepsy of infancy (SMEI), also
known as Dravet’s syndrome (Claes et al. 2001).
More than 650 heterozygous mutations of SCN1A
have been identified in patients with SMEI (∼85% of
patients tested), and approximately 20 mutations in
patients with GEFS+ (∼10% of patients tested). Half
of these mutations result in protein truncation, clearly
demonstrating haploinsufficiency of SCN1A (Meisler &
Kearney, 2005; Kearney & Meisler, 2009). The remaining
mutations are missense mutations which may cause either
gain-of-function or loss-of-function, and only a few
have been tested functionally. Interestingly, the GEFS+
mutation R1648H exhibits qualitative abnormalities in
exogenous test systems but behaves like a null allele
in knock-in mice (Martin et al. 2010). Two databases
describing published patient mutations are available at
http://www.scn1a.info (Lossin, 2009) and http://www.
molgen.ua.ac.be/SCN1AMutations/Home (Claes et al.
2009).
The extreme heterogeneity of mutations in SCN1A
is striking. Only a few sites of re-mutation have
been observed (Kearney et al. 2006a); these include
demethylation of certain CpG residues in arginine codons
and duplication of short runs of simple sequence. The
‘common disease/common variant’ hypothesis clearly
does not apply to SCN1A and epilepsy.
To address the mechanism of hyperexcitability resulting
from loss of sodium channel activity in an in vivo system,
four mouse models with null or missense mutations of
Scn1a have been developed (Table 1). Both null alleles
were generated by targeted mutagenesis in embryonic stem
Figure 1. Genomic arrangement of 10 paralogous human genes encoding α subunits of the
voltage-gated sodium channels
Protein nomenclature is indicated below the gene symbol. Arrows represent the direction of transcription. Data
from the UCSC genome browser at www.genome.ucsc.edu
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Table 1. Mouse models of sodium channel mutations and epilepsy
Gene Mutation Seizure phenotype Reference
Scn1a Targeted knock-out Spontaneous tonic and tonic-clonic Yu et al. (2006)
Scn1a Targeted knock-out Spontaneous tonic and tonic-clonic Ogiwara et al. (2007)
Scn1a R1648H BAC transgene Reduced threshold to kainic acid Tang et al. (2009)
Scn1a R1648H knock-in Spontaneous generalized, febrile, flurothyl-induced Martin et al. (2010)
Scn2a GAL879-881QQQ transgene (‘Q54’) Temporal lobe, spontaneous Kearney et al. (2001, 2006b)
Scn3a Targeted knock-out Not reported Nassar et al. (2006)
Scn8a V929F/+, –/+ Spike wave discharge, resistance to induced Papale et al. (2009)
seizures Martin et al. (2007)
Blumenthal et al. (2009)
Scn9a N641Y knock-in Reduced threshold, increased corneal kindling Singh et al. (2009)
(ES) cells (Yu et al. 2006; Ogiwara et al. 2007). Homo-
zygous null mice exhibit spontaneous seizures and die
during the third week of postnatal life. Heterozygous null
mice also exhibit spontaneous seizures, but approximately
50% survive to adulthood. Recorded sodium currents
from −/− and +/− mice revealed substantial reduction
of current density in inhibitory bipolar neurons and
cerebellar Purkinje cells, but much smaller effects in
excitatory neurons (Yu et al. 2006; Kalume et al. 2007). This
difference between inhibitory and excitatory neurons was
also observed in cortical neurons from mice carrying the
GEFS+ mutation R1648H (Martin et al. 2010). The data
from these mouse models indicate that Nav1.1 accounts
for a larger proportion of total sodium channel activity
in inhibitory neurons than in excitatory neurons and
as a consequence the net effect of Scn1a mutations is
reduced inhibitory signalling. This topic is discussed in
detail in the review by Catterall et al. in this issue.
Independent evidence for the critical role of inhibitory
signals in epileptogenesis is provided by the discovery of
heterozygosity for null alleles of the GABAA receptor in
epilepsy patients (Kang & Macdonald, 2009).
Haploinsufficiency of SCN1A
The unique haploinsufficiency of Scn1a compared with the
other sodium channels appears to be a direct consequence
of the development of severe seizures in heterozygotes.
The dependence of inhibitory neurons on the levels of
this specific sodium channel could be a consequence of
its subcellular localization, for example its function at
the axon initial segment. Deletions that disrupt two or
more of the genes in the cluster on chromosome 2q24
have been observed in patients with SMEI (Table 2). The
phenotypes of patients with multi-gene deletions are not
more severe than patients with loss-of-function of SCN1A
Figure 2. Tissue specificity and number of reported epilepsy mutations in the 9 functional voltage-gated
sodium channel genes
A, conserved domains of the sodium channel α-subunit protein. D, homologous domains; p, pore loops; L,
inter-domain loops; +, positively charged transmembrane segments contributing to voltage sensing. B, major sites
of expression of the sodium channel genes and numbers of mutations identified in patients with epilepsy.
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Table 2. Multi-gene deletions of the sodium channel cluster on chromosome
2q24 identified in patients with SMEI
Size of deletion Genes deleted No. of patients
3 to 9 Mb SCN1A, SCN7A, SCN9A, SCN2A, SCN3A 4
0.6 to 6 Mb SCN1A, SCN7A, SCN9A 9
0.2 to 0.6 Mb SCN1A, SCN9A 2
For details see Pereira et al. (2004), Madia et al. (2006), Suls et al. (2006) and
Marini et al. (2010).
alone, supporting the view that SCN1A is the only channel
that is haploinsufficient. This view is also supported by the
normal phenotypes of mice that are heterozygous for null
alleles of Scn2a (Planells-Cases et al. 2000), Scn3a (Nassar
et al. 2006) and Scn9a (Nassar et al. 2004).
SCN2A
Approximately 20 missense mutations of SCN2A have
been detected in patients with mild seizure disorders
including benign familial neonatal-infantile seizures
(BFNIS) and GEFS+. More recently, three missense
mutations of SCN2A were identified in patients with
SMEI (Ogiwara et al. 2009; Shi et al. 2009). The
SMEI mutations E211K and I1473M result in hyper-
polarizing shifts in voltage dependence of activation,
consistent with premature channel opening and hyper-
activity (Ogiwara et al. 2009). In contrast, the BFNIS
mutation R1319Q results in a depolarizing shift in voltage
dependence of activity, consistent with reduced activity
under physiological conditions (Misra et al. 2008). The
three BFNIS mutations all exhibited reduced current
density, consistent with reduced channel activity (Misra
et al. 2008). One nonsense mutation in SCN2A was
identified in a patient with intractable epilepsy and mental
decline (Kamiya et al. 2004). This mutation, R102X,
truncates the channel protein within the cytoplasmic
N-terminal domain. The authors reported a dominant
negative effect of the N-terminal fragment on activity
of the wild-type channel. Taken together, the functional
tests of SCN2A mutations suggest that the severity of the
biophysical effect is correlated with clinical severity. In the
mouse, heterozygotes for the Scn2a knockout allele were
not reported to exhibit seizures (Planells-Cases et al. 2000).
A model of temporal lobe epilepsy was generated in
the ‘Q54’ mouse strain that carries a transgene with the
gain-of-function missense mutation GAL879QQQ. This
three amino acid substitution is located in an intracellular
linker in domain 2 and results in elevated persistent
current in vivo (Kearney et al. 2001). Mice carrying the
Q54 transgene on a (B6XSJL)F1 strain background exhibit
severe spontaneous seizures with onset at 1 month and
lethality by 6 months. However, on a pure C57BL/6J back-
ground, onset is delayed and the phenotype is mild. Two
modifier loci responsible for the difference in severity
between strains C57BL/6J and SJL have been mapped,
and the evidence points to the voltage-gated potassium
channel gene Kcnv2 as one modifier (Bergren et al. 2005;
Bergren et al. 2009). The Q54 mutation also interacts with
another potassium channel, Kcnq2. Double heterozygous
mice inheriting mild alleles of Scn2a and Kcnq2 exhibit
severe myoclonic seizures (Kearney et al. 2006b). The
‘modifier’ effect of these potassium channel mutations
may be a model for gene interactions underlying human
polygenic epilepsies.
SCN3A
A single patient with partial epilepsy and a mutation in
SCN3A has been described (Holland et al. 2008). The
proband was heterozygous for the missense mutation
K354Q located in the pore loop of domain 1.
Functional studies of this lysine to glutamine substitution
demonstrated slowing of fast inactivation and increased
persistent current. Although SCN3A expression appears
to be widespread in human adult brain (Whitaker et al.
2000), in rodents the expression of Scn3a is highest in
young animals and is low in adults (Felts et al. 1997). In a
mouse with targeted inactivation of Scn3a there were no
reported spontaneous seizures (Nassar et al. 2006), but the
species difference in expression may limit the relevance of
the mouse mutant.
SCN8A
A single human family with a null muation of SCN8A
has been described (Trudeau et al. 2006). The four
heterozygous carriers of the null allele exhibited cognitive
deficits but no history of seizures. EEG studies of the
SCN8A heterozygotes were not available. However, three
mouse studies implicate Scn8a in seizures. First, a missense
mutation of Scn8a was found to ameliorate the seizure
phenotype of Scn1a null heterozygotes (Martin et al.
2007). The proposed mechanism was that reduction
of Nav1.6 in excitatory neurons reduces firing capacity
and compensates for the loss of Nav1.1 in inhibitory
neurons. In addition, Scn8a null heterozygotes were
found to be resistant to kainate- or fluorethyl-induced
seizures (Martin et al. 2007) and were also resistant to
kindling by electrical stimulation (Blumenfeld et al. 2009).
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Finally, Scn8a heterozygous null mice exhibit altered
spike wave discharges similar to the interictal patterns
seen in seizure-prone mutants (Papale et al. 2009). The
discharges were responsive to administration of the drug
ethosuximide, leading to the suggestion that SCN8A might
play a role in human absence epilepsy.
SCN9A
The major site of expression of SCN9A is in sensory
neurons of the PNS, and distinct mutations in this
channel are responsible for three inherited pain syndromes
(Dib-Hajj et al. 2009). It was therefore surprising when the
missense mutation N641Y in SCN9A was identified in a
family with febrile seizures linked to the chromosome 2q24
sodium gene cluster (Singh et al. 2009). No mutations
in SCN1A were found in this family. Furthermore, a
knock-in mouse carrying the N641Y mutation exhibited
reduced thresholds to electrically stimulated seizures.
Several patients with mutations in both SCN1A and
SCN9A were also described, but the relative contributions
of the two mutations to the patient phenotype is not yet
clear.
Sodium channel β subunit mutations and epilepsy
There are four β subunit genes in the human genome,
SCN1B to SCN4B. The β subunits are single trans-
membrane domain proteins that modulate the subcellular
localization and properties of the pore-forming α subunits
(Isom et al. 1992, 1995). The extracellular domain
of the β subunit also participates in cell–cell inter-
actions (Brackenbury et al. 2008). The recent localization
of β subunits at the action initial segment suggests
a mechanism for influence on neuronal excitability
(Brackenbury et al. 2010). A heterozygous mutation in the
extracellular domain of SCN1B encoding the β1 subunit
was first identified in a large family with GEFS+ in
1998 (Wallace et al. 1998). Several additional mutations
have been described in patients with mild epilepsies
(Wallace et al. 2002; Audenaert et al. 2003; Burgess,
2005; Yamakawa, 2005; Scheffer et al. 2007). In 2009,
the recessive mutation R125C, which prevents trafficking
of the β1 subunit to the cell surface, was identified in
a patient with SMEI (Patino et al. 2009). Homozygous
Scn1b knockout mice also exhibit spontaneous seizures
(Chen et al. 2007), confirming the role of β1 in epilepsy.
Genetic interaction between sodium channel
mutations and variants in other channels
It is evident that the firing pattern of a neuron
is determined by the net ‘channelome’ expressed in
that cell, both qualitative and quantitative. Several
examples of interactions between channel variants
have recently been described. Kearney et al. (2006b)
combined the Q54 mutation in Scn2a (described above)
with a subclinical mutation of the potassium channel
Kcnq2 and observed dramatic exacerbation of seizures.
Heterozygosity for a null mutation of Scn8a can
compensate for haploinsufficiency of Scn1a (Martin et al.
2007). Interactions between mutations of the calcium
channel gene Cacna1a and the potassium channel gene
Kcna1 have also been described (Glasscock et al. 2007). In
human epilepsy, a recent report describes modification of
the severity of SCN1A-related Dravet’s syndrome due to
co-segregation of mutations in the closely linked SCN9A
gene (Singh et al. 2009). In the future, whole genome
sequencing of epilepsy patients will reveal the extent to
which gene interaction contributes to common types of
human epilepsy.
Low level expression of neuronal channels
in non-neuronal tissues
Sensitive methods like RT-PCR and immunostaining have
detected a low level expression of sodium channels in
unexpected tissues beyond their major sites of expression.
For example, expression of brain sodium channels in
heart (e.g. Maier et al. 2003) and the heart channel in
brain (e.g. Wang et al. 2009). It is not clear whether
these low level transcripts have specific functions. Many
tissues express a low level of an alternative splice form of
SCN8A containing the exon 18N with an in-frame stop
codon that is unlikely to encode an active channel protein
(Plummer et al. 1997). In situ hybridization detects both
the full length- and truncation-encoding transcripts, but
the functional implications of the two are quite different.
One feasible approach to testing the biological function of
low-level transcripts to knock out their expression using
CRE recombinase in the mouse, but this has not yet been
reported.
Future prospects
In view of their critical role in neuronal excitability, it
is not surprising that mutations in the sodium channels
genes result in abnormal firing patterns in epilepsy.
Although the majority of mutations have been found
in the SCN1A gene, the data reviewed here suggest that
variants in several other sodium channel genes may
have a greater role in human disease than is currently
recognized. The application of new methods of whole
genome sequencing to patients with seizure disorders is
likely to replace the screening of individual candidate
genes in the future, increasing the likelihood of detecting
multiple variants in individual patients. Genetic variants
may also influence individual responses to environmental
epileptogenic exposures (Heinzen et al. 2007).
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Another new tool with considerable promise for the
study of channelopathies is the generation of neuronal
cells from skin fibroblasts taken from patients (Takahashi
& Yamanaka, 2006; Vierbuchen et al. 2010). Recent papers
describe the generation of neurons from patients with
spinal motor atrophy (Ebert et al. 2009), amyotrophic
lateral sclerosis (ALS) (Dimos et al. 2008) and Parkinson’s
disease (Soldner et al. 2009). Applied to epilepsy, this
technology will make it possible to assess the effects of
channel mutations in the context of all the other variants
in the patient’s genome, and to record from neuronal
cells that will contain tissue-specific accessory proteins
and splice factors not available in other test systems.
Current limitations include the low yield of some classes
of neurons, and the difficulty of assessing circuit-level
effects. However, preliminary studies on induced neurons
from patients with SCN1A mutations have demonstrated
that sodium currents from both excitatory and inhibitory
neurons can be recorded (unpublished observations).
This approach will make it possible to evaluate the
inhibitory-neuron hypothesis for SCN1A mutations in
human neurons and to evaluate drugs for correction of
the specific channelopathy expressed in each individual
patient.
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